Assessing methylphenidate preference in ADHD patients using a choice procedure

Fredericks, Emily Mac Donald; Kollins, Scott H.

doi:10.1007/s00213-004-1838-2

Cited by 18 publications

(18 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…66 Research performed in the 1970s revealed that stimulants do not reliably produce these subjective effects in individuals with ADHD. 67 Fredericks and Kollins 68 found that individuals with ADHD displayed a higher preference for methylphenidate compared with placebo, although other measures of abuse potential, specifically participant-rated effects of methylphenidate on mood, were not elevated. Thus, the preference for methylphenidate may reflect its therapeutic efficacy rather than abuse potential.…”

Section: Diversion Of Stimulant Medicationsmentioning

confidence: 99%

Attention-Deficit/Hyperactivity Disorder and Substance Abuse

Harstad¹,

Levy²,

Ammerman³

et al. 2014

Pediatrics

107

View full text Add to dashboard Cite

Attention-deficit/hyperactivity disorder (ADHD) and substance use disorders are inextricably intertwined. Children with ADHD are more likely than peers to develop substance use disorders. Treatment with stimulants may reduce the risk of substance use disorders, but stimulants are a class of medication with significant abuse and diversion potential. The objectives of this clinical report were to present practical strategies for reducing the risk of substance use disorders in patients with ADHD and suggestions for safe stimulant prescribing.

show abstract

Section: Diversion Of Stimulant Medicationsmentioning

confidence: 99%

Attention-Deficit/Hyperactivity Disorder and Substance Abuse

Harstad¹,

Levy²,

Ammerman³

et al. 2014

Pediatrics

107

View full text Add to dashboard Cite

show abstract

“…Kollins (2004, 2005) have also examined stimulant self-administration in ADHD populations. In a study with ADHD young adults (18-22 years), Fredericks and Kollins (2004) found greater choices of capsules containing MPH (maintenance dose) than either placebo or no-capsule options. Drug choice was more closely associated with MPHinduced reductions in ADHD symptoms than the subjective effects of the drug.…”

Section: Introductionmentioning

confidence: 99%

Measurement of the Subjective Effects of Methylphenidate in 11- to 15-Year-Old Children with Attention-Deficit/Hyperactivity Disorder

Martin

Guenthner

Bingcang

et al. 2007

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

Objective-This study examined subjective and other behavioral effects of methylphenidate (MPH) among adolescents.Methods-Standard abuse liability assessment methods that have been used in adult populations were modified for attention-deficit/hyperactivity disorder (ADHD) adolescents. MPH effects (0, 0.25 mg/kg) were evaluated under randomized, double-blind conditions in two 5-hour laboratory sessions in 24 (13 female) 11-15 year olds diagnosed with ADHD.

show abstract

“…Presumably, if this same effect were to occur in humans, exposure to a stimulant early in life might make the individual more vulnerable to developing SUD during development into adulthood. At odds with this hypothesis is some evidence suggesting that, when administered at the recommended low oral doses, abuse potential may be somewhat lower in patients with ADHD versus those without ADHD 13,14 . On the other hand, it is well established that patients with ADHD have a high risk of substance use disorders (SUDs) [15][16][17] .…”

Section: Introductionmentioning

confidence: 86%

A qualitative review of issues arising in the use of psychostimulant medications in patients with ADHD and co‑morbid substance use disorders

Kollins

2008

Current Medical Research and Opinion

View full text Add to dashboard Cite

Objective: This review addresses the relationship between attention-deficit/hyperactivity disorder (ADHD) and substance use disorders (SUDs), with an emphasis on factors that determine the potential for psychostimulant abuse. Strategies for identification and treatment of patients with ADHD who are at risk for, or have, co-morbid SUD are also addressed.Research design and methods: The article was based on a qualitative review of current literature addressing co-morbid ADHD and SUD.Discussion: Adolescent and adult patients with ADHD are at increased risk for SUD, as well as a number of other psychiatric disorders. Psychostimulant agents like methyl phenidate (MPH) and mixed amphetamine salts (MAS) are effective first-line pharmacotherapies for ADHD; however, they are Schedule II controlled substances with a potential for abuse. Evidence suggests that treatment of ADHD during childhood with stimulant agents may reduce the risk of developing SUD later on. Factors associated with the highest risk of SUD in patients with ADHD include co-morbid antisocial personality disorder, bipolar disorder, an eating disorder, severe ADHD and/or antisocial behavior symptoms, and dropping out of school. Treatment initiation during adolescence or young adulthood also has been linked to increased risk of polydrug use and non-medical stimulant use, a pattern of behavior consistent with a risk of SUD development. Treatment plans for patients with ADHD and co-morbid SUD should include behavioral interventions, careful monitoring, and when appropriate, pharmacotherapy. When oral formulations of psychostimulants are used at recommended doses and frequencies, they are unlikely to yield effects consistent with abuse potential in patients with ADHD. Long-acting stimulant formulations and non-stimulants, like atomoxetine or bupropion, have a lower potential for abuse, and provide several safe and effective treatment options for the development of a comprehensive manage ment plan for patients with co-morbid ADHD and SUD.Conclusions: The present review is neither exhaustive nor systematic. Moreover, the reviewed studies vary wide ly with regards to methodology and patient populations. In light of these limitations, several conclusions are still warranted. Patients with ADHD are at increased risk for SUD. Under certain conditions, psychostimulants may be a pharmacologic option in the treatment of patients with co-morbid ADHD and SUD. However, clinicians should be mindful of the risks and benefits of this treatment approach in a high-risk population and should also bear in mind the labeling guidelines when working with this co-morbidity.

show abstract

Assessing methylphenidate preference in ADHD patients using a choice procedure

Cited by 18 publications

References 58 publications

Attention-Deficit/Hyperactivity Disorder and Substance Abuse

Attention-Deficit/Hyperactivity Disorder and Substance Abuse

Measurement of the Subjective Effects of Methylphenidate in 11- to 15-Year-Old Children with Attention-Deficit/Hyperactivity Disorder

A qualitative review of issues arising in the use of psychostimulant medications in patients with ADHD and co‑morbid substance use disorders

Contact Info

Product

Resources

About

Assessing methylphenidate preference in ADHD patients using a choice procedure

Cited by 18 publications

References 58 publications

Attention-Deficit/Hyperactivity Disorder and Substance Abuse

Attention-Deficit/Hyperactivity Disorder and Substance Abuse

Measurement of the Subjective Effects of Methylphenidate in 11- to 15-Year-Old Children with Attention-Deficit/Hyperactivity Disorder

A qualitative review of issues arising in the use of psycho­stimulant medications in patients with ADHD and co‑morbid substance use disorders

Contact Info

Product

Resources

About

A qualitative review of issues arising in the use of psychostimulant medications in patients with ADHD and co‑morbid substance use disorders